ER-associated Ubiquitin Ligase HRD1 Programs Liver Metabolism by Targeting Multiple Metabolic Enzymes

Juncheng Wei,Yanzhi Yuan,Lu Chen,Yuanming Xu,Yuehui Zhang,Yajun Wang,Yanjie Yang,Clara Bien Peek,Lauren Diebold,Yi Yang,Beixue Gao,Chaozhi Jin,Johanna Melo-Cardenas,Navdeep S. Chandel,Donna D. Zhang,Hui Pan,Kezhong Zhang,Jian Wang,Fuchu He,Deyu Fang
DOI: https://doi.org/10.1038/s41467-018-06091-7
IF: 16.6
2018-01-01
Nature Communications
Abstract:The HMG-CoA reductase degradation protein 1 (HRD1) has been identified as a key enzyme for endoplasmic reticulum-associated degradation of misfolded proteins, but its organ-specific physiological functions remain largely undefined. Here we show that mice with HRD1 deletion specifically in the liver display increased energy expenditure and are resistant to HFD-induced obesity and liver steatosis and insulin resistance. Proteomic analysis identifies a HRD1 interactome, a large portion of which includes metabolic regulators. Loss of HRD1 results in elevated ENTPD5, CPT2, RMND1, and HSD17B4 protein levels and a consequent hyperactivation of both AMPK and AKT pathways. Genome-wide mRNA sequencing revealed that HRD1-deficiency reprograms liver metabolic gene expression profiles, including suppressing genes involved in glycogenesis and lipogenesis and upregulating genes involved in glycolysis and fatty acid oxidation. We propose HRD1 as a liver metabolic regulator and a potential drug target for obesity, fatty liver disease, and insulin resistance associated with the metabolic syndrome.
What problem does this paper attempt to address?